Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamic Characteristics of HHT120 in Healthy Subjects

Healthy Clinical Trial

— HHT120  

Official title:

A Single and Multiple Assending Doses Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamic Characteristics and Food Effect After Administration of HHT120 Capsule in Healthy Subjects

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT05414734
• Other study ID #: DTYX21037P?
• Status: Withdrawn
• Phase: Phase 1
• Start date: July 1, 2022
• Est. completion date: March 1, 2023

Study information

• Verified date: January 2023
• Source: Zhejiang Huahai Pharmaceutical Co., Ltd.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a first in human clinical trial with HHT120. The purpose of this study is to characterize the safety, pharmacokinetic (PK) and Pharmacodynamic (PD) profile of single and multiple twice-daily doses of HHT120 in healthy Subjects and to assess the effects of food on the PK profile of single-dose of HHT120 in healthy Subjects.

Description:

There are 3 parts of the study: Part 1: Single asending dose trial; Part 2: Multiple asending dose trial; Part 3: Food effect trial ( 2-Period Crossover)

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: March 1, 2023
• Est. primary completion date: February 15, 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 45 Years

Eligibility

Inclusion Criteria:

1. Subjects who understand and are willing to follow the clinical trial protocol to complete the study and sign the informed consent voluntarily

2. =50 kg, BMI 19.0-26.0 kg/m2 (including the critical value);

3. Those who have been proved healthy by medical history inquiry, physical examination and laboratory examination.

Exclusion Criteria:

1. Have a blood coagulation dysfunction or bleeding tendency, such as repeated bleeding gums, or nearly six months increased risk of bleeding events, or platelet count < 100 x 109 / L, or always have intracranial hemorrhage (after the accident, for example), gastrointestinal bleeding, purpura, or with active pathological bleeding, bleeding or have any family history, etc.

2. History of motor system, nervous/psychiatric system, endocrine system, blood circulation system, respiratory system, digestive system, urinary system, reproductive system abnormalities or existing diseases mentioned above, which the researcher judged to be clinically significant;

3. History of drug or food allergy, or are allergic to the active ingredients of the test drug and any excipient ingredients;

4. History of postural hypotension, fainting or coma;

5. High risk factors of TdP (hypokalemia, hypomagniemia, bradycardia, heart failure, hereditary long QT syndrome, etc.);

6. QTc interval greater than 450ms during screening;

7. Undergone surgery within 3 months prior to or during screening, or have undergone surgery that affects drug absorption, distribution, metabolism or excretion, or plan to undergo surgery during the study period;

8. Blood donation or massive blood loss (=400 mL) within 3 months before screening or during screening (except female menstrual period);

9. History of drug abuse or positive urine drug screening (morphine, THC, methylamphetamine, dimethylene dioxy-amphetamine, ketamine) within 5 years before screening;

10. Excessive consumption of tea, coffee or caffeinated beverages (more than 8 cups per day, 1 cup =250 mL) within 3 months prior to screening or during screening;

11. Drank regularly within 3 months prior to screening or during screening, i.e. drinking more than 14 units of alcohol per week (1 unit =360 mL beer or 45mL 40% alcohol spirits or 150mL wine), who could not abstain from drinking during the test, or whose alcohol breath test results were > 0 mg/100mL;

12. Smoking =5 cigarettes per day in the previous 3 months in the screening period; Or unable to stop using any tobacco products in the treatment period;

13. Consumed a large amount of drinks or food (such as grapefruit, grapefruit juice, grapefruit jam, etc.) rich in grapefruit, pomelo, star fruit, mango and dragon fruit within the previous 14 days prior to screening; Or any beverage or food containing grapefruit (i.e. grapefruit), pomelo, star fruit, mango, dragon fruit within 48 hours before the first dose;

14. Special dietary requirements, unable to follow the uniform diet or dysphagia;

15. Lactose intolerant (who had diarrhea after drinking milk);

16. Have used any prescription drugs, over-the-counter drugs, Chinese herbal medicines or health care products within 14 days prior to screening;

17. Received vaccination within 28 days prior to or during screening;

18. Have participated in other clinical trials within 3 months prior to or during screening or who are not themselves participating in clinical trials;

19. Pregnant or lactating women, or abnormal pregnancy tests that are clinically significant as determined by the investigator; Male subjects (or their partners) or female subjects who have planned to have children during the entire study period and within 6 months after the study end and are unwilling to use one or more non-drug contraceptive methods (e.g., complete abstinence, condoms, vasectomy, etc.) during the study period;

20. Female subjects with irregular menstruation or menstrual disorder (including menstrual cycle disorder, menstrual disorder and menorrhagia);

21. Those who cannot tolerate venipuncture or have difficulty in collecting blood;

22. Abnormal physical examination, blood routine examination, blood biochemistry, coagulation function, urine routine examination, 12-lead electrocardiogram examination, chest X-ray examination and clinical significance determined by the investigator;

23. Abnormal vital signs and abnormal retest;

24. Hepatitis B surface antigen, treponema pallidum antibody, human immunodeficiency virus antibody and hepatitis C antibody are abnormal and clinically significant as determined by researchers;

25. The investigator considers that the subjects are not suitable to participate in the study for other reasons or the subjects withdraw from the study for their own reasons.

Related Conditions & MeSH terms

• Healthy

Intervention

Drug:
• HHT120
Capsule, oral administration
• Placebo
Capsule, oral administration

Locations

Country	Name	City	State
China	Affiliated Hospital of Jiangnan University	Wuxi	Jiangsu

Sponsors (1)

Lead Sponsor	Collaborator
Shanghai Synergy Pharmaceutical Sciences Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Vital signs	Abnormal changes in vital signs from baseline	Up to Day 14
Primary	Physical examination	Abnormal changes in physical examination from baseline	Up to Day 14
Primary	Laboratory examination	Abnormal changes in laboratory examination from baseline	Up to Day 14
Primary	Electrocardiogram	Abnormal changes in electrocardiogram from baseline	Up to Day 14
Primary	Chest radiography	Abnormal changes in chest radiography from baseline	Up to Day 14
Primary	Adverse events	Incidence of adverse events, serious adverse events, adverse events of special interest	Up to Day 14
Primary	Maximum tolerable dose (MTD)	Maximum tolerable dose (MTD)	Up to Day 14
Secondary	Part 1: Cmax	Cmax of single dose administration	Up to Day 4
Secondary	Part 1: Tmax	Tmax of single dose administration	Up to Day 4
Secondary	Part 1: t1/2	t1/2 of single dose administration	Up to Day 4
Secondary	Part 1: Vz/F	Vz/F of single dose administration	Up to Day 4
Secondary	Part 1: CLz/F	CLz/F of single dose administration	Up to Day 4
Secondary	Part 1: AUC	AUC of single dose administration	Up to Day 4
Secondary	Part 2: Cmax,ss	Cmax,ss of multiple dose administration	Up to Day 10
Secondary	Part 2: AUC,ss	AUC,ss of multiple dose administration	Up to Day 10
Secondary	Part 2: Tmax,ss	tmax,ss of multiple dose administration	Up to Day 10
Secondary	Part 2: Cmin,ss	Cmin,ss of multiple dose administration	Up to Day 10
Secondary	Part 2: Cav,ss	Cav,ss of multiple dose administration	Up to Day 10
Secondary	Part 2: t1/2	t1/2 of multiple dose administration	Up to Day 10
Secondary	Part 2: MRTss	MRTss of multiple dose administration	Up to Day 10
Secondary	Part 2: Accumulation index	accumulation index of multiple dose administration	Up to Day 10
Secondary	Part 1 & Part 2: aPTT, INR and TT	Maximum percentage of aPTT, INR and TT to baseline (Emax)	Up to Day 10
Secondary	Part 3: Cmax in fasted or fed condition	Geometric mean ratios of Cmax (fed/fasted) and their 90% confidence intervals	Up to Day 4
Secondary	Part 3: AUC in fasted or fed condition	Geometric mean ratios of AUC (fed/fasted) and their 90% confidence intervals	Up to Day 4